Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06625411 · ClinicalTrials.gov registry record · Phase 3
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)
A Phase 3 study of Thyroid Eye Disease, sponsored by Viridian Therapeutics.
- Active
- Registry status
- Phase 3
- Development phase
- 117
- Enrollment target
- 20
- Study locations
NCT06625411 is a Phase 3 study of Thyroid Eye Disease that is active but no longer recruiting, run by Viridian Therapeutics. The registered enrollment target is 117 participants, above the 99-participant average among 15 other Thyroid Eye Disease trials with a reported enrollment target (18% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT06625411, a Phase 3 study of Thyroid Eye Disease, is active but no longer recruiting, sponsored by Viridian Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 117 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, VRDN-003, in participants with active Thyroid Eye Disease (TED).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG VRDN-003
Study Locations (20)
California
- Alliance Research Institute - Canoga Park - Canoga Park
- Marvel Clinical Research - Huntington Beach
- United Medical Research Institute - Inglewood
- Advancing Research International, LLC - Los Angeles
- Roski Eye Institute, Keck School of Medicine, USC - Los Angeles
- Alliance Research Institute - Lynwood - Lynwood
- A.P.J. Office - Newport Beach
- Byers Eye Institute at Stanford University - Palo Alto
- Pasadena Clinical Trials - Pasadena
- Senta Clinic - San Diego
Florida
- C&A Clinical Trials Corp - Cape Coral
- Ilumina Medical Research - Kissimmee
- Med-Care Research - Miami
- Continental Clinical Research - Miami
- Hype Clinical Research LLC - Miami
- Anmed Health Services LLC - Miami
- Sarasota Retina Institute - Sarasota
Arizona
- Scottsdale Clinical Trials - Scottsdale
Georgia
- Agile Clinical Research Trials, LLC - Atlanta
Illinois
- Vision Medical Research - Orland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2024-08-27 |
| Est. Completion | 2026-11-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06625411
The ClinicalTrials.gov registry entry for NCT06625411 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 117 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 99-participant average among 15 other Thyroid Eye Disease trials with a reported enrollment target (18% higher). The listed sponsor is Viridian Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Thyroid Eye Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06625411 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06625411 about?
NCT06625411 is a clinical study titled "An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)". This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, VRDN-003, in participants with active Thyroid Eye Disease (TED).
What is the current status of trial NCT06625411?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 117 participants. The study started on 2024-08-27. Estimated completion is 2026-11-15.
What conditions does trial NCT06625411 study?
This clinical trial studies the following conditions: Thyroid Eye Disease.
What interventions are being tested in trial NCT06625411?
The interventions under investigation include: Placebo (DRUG), VRDN-003 (DRUG).
Who is sponsoring clinical trial NCT06625411?
This trial is sponsored by Viridian Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06625411 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Eye Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)
ACTIVE NOT RECRUITING · Phase 3
-
Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
ACTIVE NOT RECRUITING · Phase 3
-
A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
ACTIVE NOT RECRUITING · Phase 3
-
A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.